Status:
TERMINATED
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborating Sponsors:
National Kidney Foundation, United States
Conditions:
Kidney Injury
Proteinuria
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test the hypothesis that isosorbide mononitrate prevents deterioration of renal function in patients receiving anti-angiogenic therapies that target vascular endothelia...
Eligibility Criteria
Inclusion
- Patients on or enrolled for anti-VEGF therapy
- new-onset proteinuria, defined as a urine protein: creatinine ratio (UPC) of \>500mg/g or hypertension (Systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg) or a decrease in eGFR by ≥ 25% from baseline before starting therapy.
Exclusion
- Pregnant women
- Breast-feeding women.
Key Trial Info
Start Date :
September 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 12 2021
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04051957
Start Date
September 26 2019
End Date
February 12 2021
Last Update
August 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University Of Texas Health Science Center at Houston
Houston, Texas, United States, 77030